Panax notoginseng Attenuates Experimental Colitis in the Azoxymethane/Dextran Sulfate Sodium Mouse Model |
| |
Authors: | Xiao‐Dong Wen Chong‐Zhi Wang Chunhao Yu Lei Zhao Zhiyu Zhang Adiba Matin Yunwei Wang Ping Li Shu‐Yuan Xiao Wei Du Tong‐Chuan He Chun‐Su Yuan |
| |
Affiliation: | 1. Tang Center for Herbal Medicine Research, University of Chicago, , Chicago, IL, 60637 USA;2. Department of Anesthesia and Critical Care, University of Chicago, , Chicago, IL, 60637 USA;3. State Key Laboratory of Natural Medicines, China Pharmaceutical University, , Nanjing, 210009 China;4. Department of Pathology, University of Chicago, , Chicago, IL, 60637 USA;5. Department of Medicine, University of Chicago, , Chicago, IL, 60637 USA;6. Ben May Department for Cancer Research, University of Chicago, , Chicago, IL, 60637 USA;7. Department of Orthopedic Surgery, University of Chicago, , Chicago, IL, 60637 USA;8. Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, , Chicago, IL, 60637 USA |
| |
Abstract: | Patients suffering from inflammatory bowel disease are at a high risk of developing colorectal cancer. To assess the anticancer potential of botanicals, in this study, we evaluated the effects of Panax notoginseng on azoxymethane/dextran sulfate sodium (DSS)‐induced colitis. One week after A/J mice received azoxymethane, the animals received DSS for 8 days or were supplemented with P. notoginseng extract, at 30 or 90 mg/kg. DSS‐induced colitis was scored with the disease activity index. The severity of the inflammatory lesions was evaluated by a colon tissue histological assessment. The expression of inducible nitric oxide synthase and cyclooxygenase‐2 (COX‐2) were also explored. We observed that the effects of P. notoginseng on the reduction of colon inflammation, expressed in disease activity index score, were in a dose‐related manner (p < 0.01). P. notoginseng inhibited the reduction of the colon length and the loss of bodyweight in dose‐related manner (all p < 0.05). The histological assessment of the colitis and inflammatory‐related immunohistochemical data also supported the pharmacological observations. Our data suggest that P. notoginseng is a promising candidate in preventing and treating colitis and inflammation‐associated colon carcinogenesis. Copyright © 2013 John Wiley & Sons, Ltd. |
| |
Keywords: | Panax notoginseng notoginseng inflammatory bowel disease colitis AOM/DSS model colorectal carcinogenesis |
|
|